世界のBiTE抗体市場(~2025):価格・売上・臨床試験インサイト

◆英語タイトル:Global BiTE Antibodies Market , Price, Sales and Clinical Trials Insight 2025
◆商品コード:KUIK21FB001
◆発行会社(リサーチ会社):Kuick Research
◆発行日:2021年2月
◆ページ数:100
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single userUSD2,000 ⇒換算¥228,000見積依頼/購入/質問フォーム
Multi UserUSD3,600 ⇒換算¥410,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はKuick Research社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Kuick Research社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

本市場調査レポートでは、世界のBiTE抗体市場について調査・分析を行い、BiTE構造&デザイン、BiTE抗体-作用機序、ブリナツモマブ(ビーリンサイト):BiTE抗体の初承認、臨床試験指標、BiTEパイプライン、市場動向、ビーリンサイトの投与量&売上高分析、二重特異性T細胞誘導の臨床パイプライン、ブリッジT細胞・腫瘍:CAR vs BiTE、研究開発、将来見通し、競争状況などを掲載しています。
・BiTE構造&デザイン
・BiTE抗体-作用機序
・ブリナツモマブ(ビーリンサイト):BiTE抗体の初承認
・臨床試験指標
・BiTEパイプライン
・市場動向
・ビーリンサイトの投与量&売上高分析
・二重特異性T細胞誘導の臨床パイプライン
・ブリッジT細胞・腫瘍:CAR vs BiTE
・研究開発
・将来見通し
・競争状況
【レポートの概要】

“Global BiTE Antibodies Market , Price, Sales and Clinical Trials Insight 2025″ Report Highlights:

Global BiTE Antibody Market Opportunity Insight (2021-2025)
Currently Only 1 BiTE Commercially Available In Market: Blinatumomab (Blincyto)
Blincyto Dosage and Market Sales Analysis ( Yearly, Quarterly and Regional Sales)
Global BiTE Antibody Clinical Trials Indicators by Phase, Company, Country, Indication and Patient Segment
Global Bispecific T-Cell Engagers Market Dynamics

The research report, “Global BiTE Antibodies Market , Price, Sales and Clinical Trials Insight 2025″ reviews about the wide spread applications of the market and how it has been able to over-come the challenges that were widely distributed in the cancer therapeutics market for long period of time. The research report summarizes about the scientific advancement that has led to the amalgamation of applications of monoclonal antibodies into the bispecific cancer antibodies and making it widely acceptable against different types of cancer indications. It is analyzed that the great ongoing trends, opportunities and desirable achievements linked with the bispecific cancer antibody therapy market is set to deliver all the essential constructive applications in terms of healthcare benefits, thus making the market highly discussed cancer therapy in the current era of pharmaceutical industry.

The unique approach of BITE antibody market, widely known as bispecific cancer antibody market involves the innovative methodology of genetic engineering in order to develop an antibody that is able to target two different epitopes at similar time, making the entire cancer targeting process more accurate when compared with monoclonal therapy. Also, the association of the entire market with strong and robust clinical pipeline and research activities in the past as well as in present is believed to completely revolutionize the entire market opportunities held within bispecific cancer antibody market.

The next generation market opportunities held within the therapy with respect to healthcare benefits and making the therapy as a standard treatment regimen are estimated to cause a substantial rise in the market growth rate when compared with other cancer therapies. The large penetration of the bispecific cancer antibody drugs against different cancer indications is also leading to cause certain changes in the entire cancer market. Some of the parameters that are believed to be responsible for the market to be driven in the next few years are: increasing cases of cancer, arrival of innovative technologies, awareness of the applications of bispecific cancer antibody market and wide range of drugs available for different diseases.

As per “Global BiTE Antibodies Market , Price, Sales and Clinical Trials Insight 2025″ report findings, it is observed that the entire market is linked with hundreds of high-performance drugs which have led to a decline in the global cancer mortality rate. The ease in the availability of the drugs and the innovative approach of increasing the target specificity are estimated to cause a radical shift in the overall acceptance of the market which was long ago observed for only some of the prominent cancer therapies such as chemotherapy. The entire market is observed to mature rapidly at global level as hundreds of bio-pharmaceutical companies and research centers are getting involved in the extension of the market by the approval of more potent drugs for commercial use. Some of the already pioneering leaders in the market is believed to be causing tremendous acceleration which is unmatchable and unimaginable for a therapy that has been discovered few decades ago. It is analyzed that the future terms of the market will make the market recognized as a standard and dominating treatment regimen for millions of patients.

【レポートの目次】

Bispecific Antibodies: The Next Generation Antibody Therapeutics
1.1 History of Bispecific Antibodies
1.2 Overview to Bispecific Antibodies

Advantages of Bispecific Antibody Over Monoclonal Antibody

BiTE (Bispecific T Cell Engager) – New Era in Cancer Immunotherapy

Structure and Design of BiTE
4.1 Construction of Single Chain Variable Fragment Antibodies
4.2 Bispecific scFv Antibody Expression and Production

BiTE Antibody – Mode of Action
5.1 Redirected Target Cell Lysis by BiTE
5.2 T-Cell Activation by BiTE
5.3 Lytic Synapse Formation by BiTE

Blinatumomab (Blincyto): The First Approved BiTE Antibody
6.1 Clinical Trials, Approval and Patenting
6.2 Design and Mechanism of Action
6.3 Adverse Drug Reactions and Management

Global BiTE Antibody Clinical Trials Indicators
7.1 By Phase
7.2 By Company
7.3 By Country
7.4 By Indication
7.5 By Patient Segment

Global BiTE Clinical Pipeline By Company, Indication and Phase
8.1 Preclinical
8.2 Phase-I

Global BiTE Antibody Market Overview
9.1 Current Market Scenario
9.2 Blincyto Reimbursement Policy

Blincyto – Dosage and Market Sales Analysis
10.1 Dosage of Blincyto in B-ALL
10.2 Current Market Sales Analysis

Clinical Pipeline of Bispecific T-Cell Engagers

Bridging T-Cells to Tumors: CAR vs BiTE

BiTE: Ongoing Research and Development
13.1 BiTE Based Immunotherapy Treatment for Relapsed Refractory Multiple Myeloma
13.2 Novel DLL3 Targeted BiTE shows Antitumor Activity in Small Cell Lung Cancer
13.3 Preliminary Efficacy of AMG 160 in Metastatic Castration – Resistant Prostate
Cancer

Global Bispecific T-Cell Engagers Market Dynamics
14.1 Favorable Market Parameters
14.2 Commercialization Challenges

Global BiTE Market Future Prospects

Competitive Landscape
16.1 Amgen
16.2 Bayers
16.3 Micromet
16.4 Psioxus Therapeutics
16.5 Y Biologics



【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[世界のBiTE抗体市場(~2025):価格・売上・臨床試験インサイト]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆